Skip to content

US · PHAR · BIOTECHNOLOGY

Pharming Group N.V. (PHAR) intrinsic value and stock valuation

$11.54as of 2026-11-21 · Mkt cap 755.56M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pharming Group N.V. DCF and intrinsic value

InvestorsCraft values PHAR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PHAR’s statements →

Pharming Group N.V. Graham Number

Graham Number: $1.87d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Leiden, ZH 2333 CR pharming.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$376.1M+12.1% 5y CAGRd
20112025
Net income
$2.85M-40.4% 5y CAGRd
20112025
Free cash flow
$54M-4.6% 5y CAGRd
20112025
Total equity
$277M+13% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$376.1M$307.8M$245.3M$205.6M$225.5M
Operating income$20.9M-$-8.93M-$-5.39M$18.2M$15.4M
Net income$2.85M-$-12.26M-$-10.55M$13.7M$18.1M
EPSd$40K-$-177.89K-$-160.58K$162.2K$206.9K
Operating cash flow$54.7M-$-1.79M-$-17.3M$22.5M$37.8M
Capital expenditure-$-760K-$-800K-$-1.46M-$-1.98M-$-16.72M
Free cash flow$54M-$-2.59M-$-18.77M$20.5M$21.1M
Total assets$499.8M$414.2M$462.9M$425.8M$450.4M
Total debt$115.8M$116.3M$171.5M$166.7M$183.4M
Net debt-$-30.25M$59.4M$109.8M-$-40.65M-$-34.2M
Total equity$277M$228.9M$218.8M$204.6M$218.7M
Cash and short-term investments$179.8M$173.9M$213.4M$207.3M$217.6M
Income statement
20252024202320222021
Revenue$376.1M$307.8M$245.3M$205.6M$225.5M
Cost of revenue$45.5M$36.7M$25.2M$17.6M$24M
Gross profit$330.6M$271.1M$220.1M$188.1M$201.5M
Research and development expenses$100.4M$86.1M$68.9M$52.5M$79.8M
Selling, general and administrative expenses$117.4M$102.7M$87.5M$68.9M$54.6M
Other expenses$92M$91.2M$69.1M$48.4M$51.8M
Operating expenses$309.8M$280M$225.5M$169.8M$186.1M
Cost and expenses$355.3M$316.7M$250.7M$187.4M$210.1M
Interest income$2.18M$5.92M$3.53M$90K$60K
Interest expense$10.7M$9.05M$5.96M$5.36M$7M
Depreciation and amortization$11.2M$16.6M$15.9M$13.2M$22.2M
Ebitda$34.8M$16.9M$9.88M$33.5M$55.3M
Operating income$20.9M-$-8.93M-$-5.39M$18.2M$15.4M
Total other income/expenses, net-$-8.03M$130K-$-6.62M-$-3.25M$10.8M
Income before tax$12.9M-$-8.79M-$-12.01M$15M$26.2M
Income tax expense$10.3M$3.47M-$-1.46M$1.31M$8.03M
Net income$2.85M-$-12.26M-$-10.55M$13.7M$18.1M
Weighted average shares outstanding$71.3M$68.9M$65.7M$82.5M$87.6M
Weighted average diluted shares outstanding$71.3M$68.9M$65.7M$84.3M$87.6M
Balance sheet
20252024202320222021
Cash and short-term investments$179.8M$173.9M$213.4M$207.3M$217.6M
Net receivables$54.7M$52M$42.6M$25.3M$31.3M
Inventory$64.9M$57.7M$56.8M$42.3M$31M
Total current assets$299.4M$288.3M$316.3M$277.5M$282.8M
Property, plant and equipment, net$24M$24.1M$33.5M$39.2M$37.6M
Goodwill and intangible assets$135.5M$63.2M$71.3M$75.1M$95M
Long-term investments$9.87M$4.38M$10.4M$9.73M$9.81M
Total non-current assets$200.4M$125.9M$146.5M$148.3M$167.6M
Total assets$499.8M$414.2M$462.9M$425.8M$450.4M
Accounts payable$105.9M$10.5M$16M$8.75M$8.62M
Short-term debt$8.71M$7.45M$5.44M$5.23M$4.87M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$115.8M$76.4M$78M$59.7M$53M
Long-term debt$107.1M$108.9M$166.1M$161.5M$178.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$107.1M$108.9M$166.1M$161.5M$178.7M
Capital lease obligations$17.7M$31M$33.1M$33.3M$23.7M
Total liabilities$222.8M$185.3M$244.1M$221.2M$231.7M
Common stock$8.01M$8.04M$7.67M$7.51M$8.42M
Retained earnings-$-272.9M-$-285.27M-$-265.26M-$-256.43M-$-309.69M
Accumulated other comprehensive income (loss)$0.00-$-220K-$-2.06M-$-8.74M$3.85M
Total equity$277M$228.9M$218.8M$204.6M$218.7M
Total investments$43.7M$121.3M$162.1M$9.73M$9.81M
Total debt$115.8M$116.3M$171.5M$166.7M$183.4M
Net debt-$-30.25M$59.4M$109.8M-$-40.65M-$-34.2M
Cash flow statement
20252024202320222021
Net income$12.9M-$-8.49M-$-12.01M$15M$23.1M
Depreciation and amortization$11.2M$16.1M$15.9M$13.2M$19.6M
Stock-based compensation$13.8M$11.3M$9.25M$6.39M$9.06M
Change in working capital$10.4M-$-10.07M-$-16.96M-$-390K-$-4.96M
Accounts receivable-$-3.35M-$-6.78M-$-18.54M$2.36M$5.92M
Inventory-$-1.29M-$-500K-$-14.43M-$-15.02M-$-6.15M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$54.7M-$-1.79M-$-17.3M$22.5M$37.8M
Investments in property, plant and equipment-$-760K-$-800K-$-1.46M-$-1.98M-$-16.72M
Acquisitions, net-$-58.22M$0.00$0.00$7.3M$0.00
Net cash used for investing activities$26.3M$31.6M-$-129.39M$5.32M-$-21.3M
Common stock issued$19.8M$5.58M$8.13M$2.28M$4.72M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.5M-$-34.41M-$-1.04M-$-4.98M-$-27.95M
Net change in cash$90.4M-$-6.8M-$-145.6M$15.4M-$-13.23M
Cash at end of period$145.3M$54.9M$61.7M$207.3M$191.9M
Operating cash flow$54.7M-$-1.79M-$-17.3M$22.5M$37.8M
Capital expenditure-$-760K-$-800K-$-1.46M-$-1.98M-$-16.72M
Free cash flow$54M-$-2.59M-$-18.77M$20.5M$21.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pharming Group N.V.

        Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

        CEO
        Fabrice Chouraqui
        Employees
        407
        Beta
        0.09

        Explore

        Frequently asked questions

        What is the intrinsic value of Pharming Group N.V. (PHAR)?

        InvestorsCraft does not currently publish an intrinsic value for PHAR. How the IC value is calculated.

        Is PHAR undervalued?

        InvestorsCraft does not publish an undervaluation signal for PHAR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.